62868-43-3

Usage

Uses

Used in Pharmaceutical Research:
1-(2-Methoxyphenyl)imidazolidin-2-one is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and chemical properties facilitate the creation of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(2-Methoxyphenyl)imidazolidin-2-one serves as a valuable building block for constructing complex molecular structures. Its versatility allows for the development of a wide range of chemical products.
Used in Medicinal Chemistry Research:
MIPO is used as a target for medicinal chemistry research due to its potential anticonvulsant and analgesic properties. Its unique structure makes it an attractive candidate for the development of new drugs to treat various medical conditions.
Used in the Synthesis of Biologically Active Compounds:
1-(2-Methoxyphenyl)imidazolidin-2-one is utilized as a starting material for the synthesis of biologically active compounds, which can be applied in various therapeutic areas, including the treatment of neurological disorders, pain management, and other medical applications.

Upstream product

• 120-93-4 imidazolidone 
• 529-28-2 4-iodoanisol 
• 90-04-0 2-methoxy-phenylamine 
• 36908-21-1 N¹-(2-methoxy-phenyl)-ethane-1,2-diamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 62868-41-1 3-(2-methoxy-phenyl)-2-oxo-imidazolidine-1-carbonyl chloride 
• 85834-33-9 2-[3-(2-Methoxy-phenyl)-2-oxo-imidazolidin-1-yl]-acetamide 

Relevant academic research and scientific papers

Mild, convenient and versatile Cu-mediated synthesis of N-aryl-2-imidazolidinones

A mild, general, convenient and practical methodology for the selective copper-mediated mono N-arylation of unprotected 2-imidazolidinone was developed. Strong electron-donating groups and free hydroxy and amino groups on the aryl iodide substrates were well tolerated. The use of n-butanol as the solvent for the copper-catalysed mono-arylation of 2-imidazolidinone is unprecedented.

ADRENERGIC RECEPTOR ANTAGONISTS

The present invention relates to α1a and/or α1b adrenergic receptor antagonists, which can be used to treat a disease or disorder mediated through α1a and/or α1b adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.

Synthesis of a new family of N-aryl lactams active on chemesthesis and taste

A new class of synthetic compounds with chemesthetic activity has been identified. They have been designed ex-novo by structural similarity with known cooling compounds such as menthol, icilin and cyclic ketoenamines. 19 new derivatives have been obtained

Lithiation of 1-arylimidazol-2(1H)-ones and 1-aryl-4,5-dihydroimidazol- 2(1H)-ones

1-Arylimidazol-2(1H)-ones are shown to be readily lithiated, using 2 mol equiv. of n-butyllithium, on the benzene ring, ortho to the heterocycle. 1-Aryl-4,5-dihydroimidazol-2(1H)-ones also undergo metalation on the aromatic substitutuent ortho to the heterocycle, but less efficiently. 1-Aryl-3-methylimidazol-2(1H)-ones are lithiated on the heterocyclic ring and then on the benzene ring ortho to the heterocycle. No ortho-directing effect was found for 1-aryl-4,5-dihydro-3-methylimidazol-2(1H)-ones.